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Introduction {#sec1}
============

Primordial germ cells (PGCs) are the precursors of the fully differentiated gametes, oocytes, and sperm, establishing during their development the prerequisites of the totipotent state. Upon their specification PGCs undergo global epigenetic reprogramming, erasing epigenetic memory and re-establishing an epigenetic ground state ([@bib9], [@bib57], [@bib42]). Our basic understanding of mammalian PGC specification and epigenetic reprogramming stems largely from work in the mouse. However, recent work is beginning to shed light on human germline development and epigenetic reprogramming ([@bib44], [@bib50]). In the mouse, after exit from naive pluripotency in the inner cell mass (ICM) and priming for differentiation, a small cluster of ∼40 PGCs is detectable in the epiblast around embryonic day 7.25 (E7.25). Subsequently PGCs migrate through the hindgut to the developing genital ridges (E8--E10.5) where they proliferate extensively before sexual differentiation commences. Human PGCs (hPGCs) are specified around E12--E16 (developmental week 2), and, while the early migratory phase (weeks 3--5) of in vivo hPGC development is currently not accessible to experimental analysis, gonadal hPGCs have recently been isolated and characterized molecularly ([@bib15], [@bib17], [@bib52]). This in vivo work has shown that hPGCs are characterized by the expression of known PGC marker genes such as *BLIMP1*, *PRDM14*, or *DPPA3* but also express human specific genes such as *SOX17*. Similar to epigenetic reprogramming in mouse PGCs (mPGCs), in vivo hPGCs have erased DNA methylation globally by week 5.5, presumably starting during the migratory phase, resulting in a hypomethylated epigenetic ground state.

Given the relative inaccessibility and difficulties in manipulating PGCs in vivo, the development of an in vitro differentiation system is highly desirable. Spontaneously differentiating human and mouse cells expressing germ cell markers isolated from embryoid bodies (EBs) were initially used as a proxy for in vitro generation of gametes or PGCs ([@bib11], [@bib45]), and some erasure of DNA methylation was documented in the mouse system ([@bib56]). However, only more recent studies have demonstrated the potential to faithfully reconstitute early mouse and human PGC specification in vitro ([@bib21], [@bib24], [@bib46], [@bib49]). Some limited results suggested that DNA methylation reprogramming takes place, but no systematic genome-scale analysis has been carried out ([@bib21], [@bib52]).

The specification of mouse PGC-like cells (mPGCLCs) closely recapitulates in vivo PGC specification ([@bib21]). Naive ICM-like embryonic stem cells (ESCs) ([@bib38]) are differentiated to epiblast-like cells (EpiLCs), which closely mimic the in vivo epiblast state around E6.25, when mPGCs are first specified. "Germline-competent" EpiLCs then progress toward mPGCLCs, which have the potential to generate oocytes ([@bib22]) and spermatid-like cells ([@bib65]). Human PGCLC (hPGCLC) specification protocols thus far started from already "germline-competent pluripotent stem cells" ([@bib24]), thereby not fully recapitulating the in vivo hPGC specification and raising the possibility that key epigenetic steps during the priming phase were missed ([@bib44]). The recent establishment of naive hESC culture conditions ([@bib18], [@bib51], [@bib53], [@bib54]), which more closely resemble the in vivo state of naive human ICM cells, provides a promising opportunity to reconstitute more faithfully hPGC specification in vitro.

Here we report the establishment of a protocol for in vitro hPGCLC specification from naive hESCs and investigate the early events of DNA methylation remodeling prior to and during PGCLC specification. We have also undertaken a comparative analysis of epigenetic reprogramming at single base resolution during human and mouse in vitro germline development and have identified conserved as well as divergent mechanisms regulating the observed DNA methylation dynamics. This work establishes a tractable model system for the precise study of epigenetic reprogramming in the germline, and describes the principles and dynamics of DNA methylation remodeling during early PGC specification.

Results {#sec2}
=======

Generation of Human and Mouse PGCLCs from Naive ESCs {#sec2.1}
----------------------------------------------------

Using a similar strategy to that described for mPGCLC specification ([@bib21]) we differentiated naive hESCs toward hEpiLCs in serum-free N2B27 medium containing transforming growth factor β (TGF-β), basic fibroblast growth factor (bFGF), and knockout serum replacement (KSR) ([Figure 1](#fig1){ref-type="fig"}A). Naive hESC colonies\' typical domed shape was lost and hEpiLCs adopted a flat, primed cell morphology by day 4 ([Figure 1](#fig1){ref-type="fig"}B), a characteristic also observed during mPGCLC differentiation ([@bib21]). Next we aggregated hEpiLCs to EBs (day 0) and induced hPGCLC specification by adding bone morphogenetic protein 4 (BMP4), stem cell factor (SCF), epidermal growth factor (EGF), and leukemia inhibitory factor (LIF). Using a GFP reporter expressed under the control of the *OCT4*-dPE promoter ([@bib53]) we were able to monitor the activity of the naive and germ cell-specific *OCT4*-dPE promoter ([@bib53], [@bib62]) in the EBs, suggesting the formation of hPGCLCs ([Figure 1](#fig1){ref-type="fig"}B). Since previous in vivo studies have shown that hPGC development is not completed by week 5.5 ([@bib52]), we aimed to progress hPGCLC differentiation as far as possible and achieved the formation and collection of EBs with normal morphology and no signs of apoptosis until day 12 after induction. We next used fluorescence-activated cell sorting (FACS) for cKIT-positive cells to isolate putative hPGCLCs ([Figure 1](#fig1){ref-type="fig"}C), a strategy that has been shown to result in 100% pure germline cells in vivo ([@bib14], [@bib15]). The hPGCLC population expressed key hPGC marker genes such as *BLIMP1*, *SOX17*, or *NANOS3* and not *SOX2* ([Figures 1](#fig1){ref-type="fig"}D--1F), indicating successful hPGCLC specification.

We also generated mPGCLCs as previously described ([Figure S1](#mmc1){ref-type="supplementary-material"}) ([@bib21]). Naive mESCs were differentiated to mEpiLCs, aggregated to form EBs, and further progressed toward the mPGC fate using BMP4, SCF, LIF, and EGF, as evidenced by the expression of a *Blimp1*:Venus reporter ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Using FACS we were able to isolate mPGCLCs that expressed *Stella*:CFP and *Blimp1*:Venus reporters and/or were marked by the surface proteins SSEA1 and CD61 ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). mPGCLCs expressed key PGC marker genes, such as *Stella*, *Blimp1*, or *Prdm14*, not or only weakly expressed in EpiLCs ([Figure S1](#mmc1){ref-type="supplementary-material"}E).

We carried out RNA sequencing (RNA-seq) ([Table S1](#mmc1){ref-type="supplementary-material"}) and using unsupervised hierarchical clustering from human and mouse naive ESC, primed EpiLCs, and sorted cKIT^+^ human or SSEA1^+^/CD61^+^ mPGCLCs, found that PGCLCs cluster separately from naive and primed cells ([Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G). While mPGCLCs showed a preference to separate by time points, suggesting a temporal progression, the different hPGCLC time points were intermingled, indicating smaller temporal changes. Principal component analysis (PCA) confirmed these observations ([Figures 1](#fig1){ref-type="fig"}G and 1H) and showed that during specification of PGCLCs from naive ESCs, some of the transcriptional variance between naive and primed cells (PC2) was reversed during primed to PGCLC differentiation, suggesting re-establishment of a more "naive" transcriptional signature in PGCLCs.

Global Epigenetic Changes during Human and Mouse PGCLC Specification {#sec2.2}
--------------------------------------------------------------------

To gain insights into epigenetic reprogramming during in vitro PGCLC specification, we performed whole-genome bisulfite sequencing of human and mouse PGCLCs and primed EpiLCs ([Table S1](#mmc1){ref-type="supplementary-material"}), and in our analysis included published in vivo and in vitro datasets ([@bib12], [@bib16], [@bib39], [@bib47], [@bib51], [@bib52], [@bib60]) ([Figures 2](#fig2){ref-type="fig"} and [S2](#mmc1){ref-type="supplementary-material"}). After fertilization, the highly methylated epigenome of sperm and to a lesser extent of oocytes is globally erased during progression to ICM and naive ESCs (∼29% in hESCs and ∼31% in mESCs). Subsequently, there was a strong de novo methylation activity during priming of human and mouse EpiLCs, which increased the average CpG methylation levels to ∼65% ([Figures 2](#fig2){ref-type="fig"}A and 2B), equivalent to the methylation levels found in mouse epiblast at E6.5 ([@bib47]). We confirmed this remethylation using liquid chromatography followed by mass spectrometry, showing an increase from approximately 1.5%--4% of all cytosines being methylated from the naive ESC state to day-4 hEpiLCs and day-2 mEpiLCs, respectively ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). We also observed an approximately 2-fold increase in 5-hydroxymethylcytosine (5hmC) levels in mouse and human EpiLCs compared with naive ESCs. Interestingly, the remethylation phase during priming took twice as long in humans than in mice, suggesting a different regulation of the de novo methylation machinery. In line with increased methylation activity, the expression levels of the de novo *DNMT*s *3A* and *3B* were upregulated in both mouse and human primed cells, albeit the increase in mouse was much more pronounced ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}C).

Next we analyzed epigenetic changes during early PGC specification. mPGCLCs rapidly lost global methylation, reaching levels of around 40% CpG methylation after 4 days and 24% CpG methylation at day 6, similar to in vivo PGCs at E10.5 (∼28%) or E11.5 (∼20%) ([@bib47]). In contrast, hPGCLCs demethylated much more slowly, gradually decreasing global levels of CpG methylation from approximately 68% at day 4 to 55% at day 12 ([Figures 2](#fig2){ref-type="fig"}A and 2B). In line with this, previous reports using immunofluorescence to assess 5hmC levels in day-4 hPGCLCs found only a small decline in 5hmC ([@bib24]), while in vivo hPGCs demethylate to approximately 25% CpG methylation by week 5.5 and reach their lowest levels of CpG methylation (∼8%) not before week 7 ([@bib15], [@bib17], [@bib52]). On average, therefore, mouse PGC methylation reprogramming is 5-fold faster than that in human PGCs.

The expression of de novo *DNMTs* was reduced slightly in human and stronger in mouse PGCLCs ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}C) with further downregulation in in vivo hPGCs. Transcript levels of the TET proteins, which have been implicated in imprint erasure in PGCs ([@bib19]), were upregulated in hPGCs, mPGCs, and mPGCLCs but not in hPGCLCs. However, while transcript levels of *UHRF1* were substantially decreased in mPGCLCs and in vivo mPGCs, with remaining protein being excluded from the nucleus ([@bib47]), they were only slightly decreased in hPGCLCs and UHRF1 protein remained nuclear ([Figure S2](#mmc1){ref-type="supplementary-material"}D). This differential regulation would result in substantially different kinetics of passive demethylation in mouse versus human PGCs.

The methylation pattern over genes, with low methylation at the transcription start sites (TSSs) and slightly increased levels over gene bodies, was maintained during mouse and human PGCLC specification ([Figures 2](#fig2){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}E). DNA methylation at introns, exons, non-CpG island (CGI)-containing promoters, or intergenic regions ([Figures 2](#fig2){ref-type="fig"}E and [S2](#mmc1){ref-type="supplementary-material"}F) followed the trend of the whole genome, while non-promoter CGIs and CGI-containing promoters remained at low levels of methylation throughout all time points with a small increase during EpiLC priming. Next we analyzed the methylation at known differentially methylated regions (DMRs) of imprinted genes ([Figures 2](#fig2){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}G). Methylation of paternal or maternal DMRs was exclusively found in either sperm or oocytes, respectively; after fertilization the combined levels were maintained at around 50% into ICM cells, indicating faithful maintenance of imprinting. Naive mESCs and mEpiLCs maintained a similar methylation pattern of imprinted DMRs, which notably were subsequently erased during mPGCLC formation, with substantial erasure in day-6 mPGCLCs. In vivo mPGCs also demethylate the imprinted DMRs, starting around E10.5/E11.5 with complete erasure by E13.5. In contrast, naive hESCs had erased almost all imprinted DMRs, as previously reported ([@bib40]) and, as a consequence, imprinted DMRs were not re-established during hEpiLC priming and remained demethylated during hPGCLC specification at levels comparable with in vivo hPGCs.

To identify specific unique regions showing different methylation dynamics compared with the whole genome during the early phase of human epigenetic resetting, we performed k-means clustering of 2-kb probes of the genome ([Figure 2](#fig2){ref-type="fig"}G), excluding probes overlapping with repetitive elements, which were analyzed separately ([Figures 4](#fig4){ref-type="fig"} and [S4](#mmc1){ref-type="supplementary-material"}). The identified clusters showed enrichment for specific genomic features, with clusters 3 and 6 being enriched for intergenic regions and mostly following closely the global trend of DNA methylation. Clusters 2 and 7 retained low methylation and were enriched in CGIs, with cluster 2 showing enrichment in promoter and genic CGIs, while cluster 7 was enriched in intergenic CGIs. Cluster 4 retained higher levels of DNA methylation even in in vivo hPGCs and, while no specific enrichment was found, most probes were in close proximity (\<2 kb) to SINE-VNTR-Alu (SVA) or L1Pa repetitive elements. Cluster 1 followed the general methylation pattern overall but retained slightly higher levels of methylation in hPGCLCs and was enriched for gene bodies.

Regulation of Local Methylation Dynamics {#sec2.3}
----------------------------------------

Having found that the feature composition and proximity to repetitive elements correlates with the methylation dynamics, we first compared the local methylation levels of primed day-4 hEpiLCs with day-12 hPGCLCs. The overall methylation distribution showed that the genome was not demethylated uniformly; we thus constructed a background model of demethylation from primed day-4 hEpiLCs to day-12 hPGCLCs and tested for probes with significantly (p \< 0.05) higher (red) or lower (blue) levels of DNA methylation ([Figure 3](#fig3){ref-type="fig"}A).

A subset of probes with significantly lower levels of DNA methylation in day-12 hPGCLCs overlapped with CGIs, which remained lowly methylated throughout the whole time course (compare clusters 2 and 7 in [Figure 2](#fig2){ref-type="fig"}G). We then looked for genomic features overlapping with the more highly methylated regions ([Figure 3](#fig3){ref-type="fig"}A) and found that probes overlapping with gene bodies or the repetitive elements SVA and L1Pa, which had previously been found to resist demethylation in in vivo hPGCs ([@bib52]), retained higher levels of DNA methylation in day-12 hPGCLCs. This can also be seen in the illustrated example ([Figure 3](#fig3){ref-type="fig"}B), where SVA overlapping probes (green shading) or gene bodies of *ASXL2* or *RAB10* (red shading) retained higher levels of methylation, even in in vivo week-5.5 hPGCs. Increased DNMT3B binding and de novo methylation at transcribed genes has been reported previously ([@bib2]) but we did not find a correlation between persistence of gene body methylation and transcription in day-12 hPGCLCs ([Figure S3](#mmc1){ref-type="supplementary-material"}A).

We next compared the methylation levels of the probes identified with significantly higher (red) or lower (blue) levels of DNA methylation ([Figure 3](#fig3){ref-type="fig"}A) across the whole time course of in vitro hPGCLC specification, including earlier and later in vivo datasets ([Figure 3](#fig3){ref-type="fig"}C). Regions that partially resisted demethylation during hPGCLC specification (red) showed higher methylation in naive hESCs and hICM but acquired methylation levels comparable with that of the whole genome upon priming and remethylation (day-4 hEpiLCs). During subsequent hPGCLC differentiation, these regions retained higher levels of methylation until in vivo week-5.5 hPGCs and only became almost completely demethylated in week-7 hPGCs, indicating that DNA demethylation kinetics differ significantly across the genome.

To better understand the regulation of local methylation dynamics, we performed a similar analysis on the mouse datasets ([Figure 3](#fig3){ref-type="fig"}D) and compared the methylation levels of day-2 mEpiLCs with globally demethylated day-6 mPGCLCs. A defined set of regions retained high levels of methylation in mPGCLCs and these were enriched in intracisternal A particle (IAP) transposable elements (TEs), but there was no enrichment in gene body methylation as observed in human. As illustrated in [Figure S3](#mmc1){ref-type="supplementary-material"}B, not all regions that retain methylation in mPGCLCs (and in vivo mPGCs) are IAP associated. We therefore overlaid the methylation comparison with available chromatin immunoprecipitation sequencing (ChIP-seq) data from day-6 mPGCLCs ([@bib30]) or in vivo mPGCs ([@bib33]). Regions retaining high levels of DNA methylation were enriched in the repressive histone marks histone 3 lysine 9 trimethylation (H3K9me3) or H3K9me2 ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}C), which have been shown to play a pivotal role in recruitment of the DNA methylation machinery ([@bib8], [@bib26], [@bib43]). Conversely, regions with low levels of DNA methylation in day-6 mPGCLCs were enriched in the activating histone marks H3K4me3 or H3K27ac ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}C).

The transcript levels of the H3K9 methylases *EHMT1* and *EHMT2* were reduced in PGCLCs and in vivo PGCs of both species, while the expression of the H3K9 demethylases *KDM3A* and *KDM3B* was increased in only mPGCLCs and in vivo PGCs of both species ([Figures 3](#fig3){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}D), but not in hPGCLCs.

Regulation of Transposable Elements in PGCLCs {#sec2.4}
---------------------------------------------

About half of the mammalian genome is composed of interspersed repetitive elements resulting from replicative insertion events of TEs ([@bib4], [@bib31], [@bib36]). DNA methylation is important for TE repression in somatic cells, and other mechanisms including histone modifications or PIWI-interacting RNAs (piRNAs) control TEs upon global demethylation ([@bib13], [@bib25]). We analyzed the average methylation levels of major classes of human and mouse TEs, including long and short interspersed elements (LINEs and SINEs), long terminal repeats, human SVA retrotransposons, and mouse IAPs (the most active murine TE class).

All TEs gained methylation during priming from naive hESCs to hEpiLCs and only became demethylated slowly during hPGCLC specification ([Figure 4](#fig4){ref-type="fig"}A), with SVA elements retaining most methylation, while in vivo hPGCs showed demethylation with only SVA and human endogenous retrovirus K (hERVK) TEs retaining some methylation at week 7 ([@bib52]). Naive hESCs showed high expression of SVA TEs but transcription of TEs was generally low in hPGCLCs and hPGCs, with the exception of hERVK elements, which showed some expression in all datasets ([Figure S4](#mmc1){ref-type="supplementary-material"}A).

In contrast, there was extensive demethylation of TEs during mPGCLC development ([Figure 4](#fig4){ref-type="fig"}B), again resembling levels of in vivo mPGCs around E10.5/E11.5. IAPs retained higher levels of methylation in vitro, as they do in vivo. Analysis of poly(A)-enriched RNA-seq datasets ([Figure 4](#fig4){ref-type="fig"}C) showed increased expression of IAPs and ERVK in day-6 mPGCLCs. Transcription of other TEs remained low in all mPGCLC datasets, suggesting that additional repressive mechanisms are controlling TE expression. Previous studies using total RNA-seq have also shown increased TE expression in hypomethylated in vivo mPGCs and an involvement of piRNAs in controlling TE expression ([@bib35]).

piRNAs are germline-specific 24- to 31-nt-long small RNAs (smRNAs) which have been shown to regulate the activity of TEs in the germline ([@bib1]). Due to the lack of suitable mammalian experimental models, the mechanisms controlling the generation of mature piRNAs and their molecular TE-silencing activity are still enigmatic ([@bib25]). Notably, mPGCLCs do express the relevant enzymes required for piRNA biogenesis and activity, namely *Miwi2* and *Mili* ([Figure 4](#fig4){ref-type="fig"}D) while expression of *MILI* and *MIWI2* in hPGCLC is lower than in in vivo hPGCs ([Figure S4](#mmc1){ref-type="supplementary-material"}B), perhaps as a consequence of the fact that TEs are not yet demethylated and hence not prone to transcriptional activation.

We generated small RNA-seq libraries from mPGCLCs and in vivo E15.5 male prospermatogonia ([Table S1](#mmc1){ref-type="supplementary-material"}) to assess the expression of piRNAs. mPGCLCs and prospermatogonia showed strong enrichment in 24- to 31-nt-long smRNAs with high numbers mapping to gene-derived piRNAs ([@bib32]) and \>50% of all smRNAs mapping to TEs ([Figures 4](#fig4){ref-type="fig"}E, 4F, and [S4](#mmc1){ref-type="supplementary-material"}C). In contrast, mESC-derived smRNAs were mostly 22--23-nt-long microRNAs (miRNAs). Furthermore, we found characteristics of piRNAs ([@bib25]) in the smRNAs from mPGCLC and prospermatogonia samples that mapped to repetitive elements (defined by repeatmasker): smRNAs mapping to TEs had a tendency for U at the 5′ end ([Figures 4](#fig4){ref-type="fig"}G and [S4](#mmc1){ref-type="supplementary-material"}D) and also a high frequency of exactly 10-nt spaced 5′ to 5′ overlaps ("ping-pong signature") ([Figure 4](#fig4){ref-type="fig"}H). Similarly, we found high numbers of smRNAs mapping both sense and antisense to repetitive elements in mPGCLCs ([Figure 4](#fig4){ref-type="fig"}I). Notably, therefore, in vitro mPGCLCs express transposon-derived piRNAs at levels comparable with those of in vivo prospermatogonia.

Discussion {#sec3}
==========

Global DNA demethylation is a key characteristic of mammalian PGC (and early embryo) development and allows the germ cell lineage to create a blank slate ("tabula rasa") ([@bib9]) with an underlying pluripotent characteristic, possibly a prerequisite for the subsequent generation of the totipotent zygote ([@bib42]). Here we have developed a protocol for hPGCLC formation from naive ESCs, hence recapitulating in vivo priming and specification, and studied the early events of DNA methylation reprogramming in human and mouse PGCLCs. This approach has also allowed us to characterize the DNA methylation changes during the initial priming phase toward EpiLCs, which formed the basis for the subsequent demethylation during PGCLC specification, and to obtain insights into the regulation of epigenetic resetting in human and mouse. Notably, there are some key differences in the regulation of epigenetic modifiers, which may underlie the very different reprogramming kinetics in human and mouse.

We discovered that human and mouse PGCLCs can be induced from naive pluripotent stem cells using similar methodologies, despite the fact that the transcriptional networks regulating human and mouse PGC specification differ in several aspects ([@bib44]). Notably, in vitro hPGCLC development was significantly delayed compared with mPGCLC specification, which is in agreement with the different developmental timing in vivo ([@bib23]). Interestingly, the rate of de novo methylation during priming to EpiLCs was approximately twice as fast in mouse as in human, although the final methylation levels were comparable. This correlated with strong upregulation of all de novo *Dnmt*s in the mouse, while human primed cells only showed a modest increase in *DNMT3A* and *DNMT3B* expression and a decrease in *DNMT3L* mRNA levels, potentially explaining species-specific differences in de novo methylation kinetics during priming. Similarly, the rate of global DNA demethylation was slower in hPGCLCs, reaching ∼55% CpG methylation after 12 days compared with ∼25% CpG methylation in day-6 mPGCLCs. In human this represents early demethylation steps not captured in vivo so far ([@bib15], [@bib17], [@bib52]) while in mouse the end point corresponds to late migratory (E10.5/E11.5) mPGCs ([@bib47]). Hence, taking both in vitro and in vivo data into account it appears that demethylation in mouse PGCs is five times as fast as in human ones, which is unlikely to be solely due to different rates of cell proliferation.

Mechanistically, some of these global differences may instead be explained by species- and stage-specific regulation of the DNA maintenance methylation machinery. mPGCLCs (and mPGCs) repress *Uhrf1* strongly at the transcriptional level, while hPGCLCs show only weak repression. In hPGCs, however, *UHRF1* is repressed at the transcript level and strongly at the protein level ([@bib15], [@bib17], [@bib52]), suggesting that impairment of DNA maintenance methylation varies between different stages of hPGC development. Remaining UHRF1 protein was found to be excluded from the nucleus in mPGCs ([@bib47]) while in hPGCLCs and hPGCs it remains nuclear ([@bib24], [@bib52]).

*Prdm14* has been shown to be critical for mouse PGC development ([@bib61]) and, together with *Blimp1*, is implicated in the transcriptional repression of de novo *Dnmt*s and *Uhrf1* ([@bib37]). During hPGC development upregulation of *PRDM14* is delayed compared with other germ cell genes ([@bib24], [@bib52]), which might explain the species-specific temporal differences in the regulation of de novo *DNMT*s and *UHRF1*.

Maintenance methylation is regulated by synergistic action of UHRF1 and H3K9me2 and H3K9me3, so it was interesting to note that both mPGCLCs and mPGCs showed repression of *Ehmt1* and *2* (H3K9 methylases) and increased expression of *Kdm3a* and *3b* (H3K9 demethylases), potentially driving loss of H3K9 methylation together with reduced recruitment of UHRF1 to the replication fork and ensuing erosion of DNA maintenance methylation ([@bib58]). During hPGCLC specification, *EHMT1* and *EHMT2* expression was also reduced but *KDM3A* and *KDM3B* expression was only increased in hPGCs, suggesting that loss of H3K9me2 is also slower in hPGC development. Hence there is apparently a finely tuned system of differential regulation of de novo and of maintenance methylation modifiers that results in considerably slower epigenetic reprogramming kinetics in human versus mouse PGCs.

Demethylation was, however, not uniform across the genome. Regions overlapping with young and active TEs ([@bib13]) partially resist DNA demethylation in PGCLCs, as they do in in vivo PGCs ([@bib15], [@bib17], [@bib27], [@bib47], [@bib52]). IAPs, which are the youngest and most active TEs in the mouse germline, are most resistant to demethylation, while none of the human TE families were as resistant, consistent with human TEs being more endogenized ([@bib13]). In addition to TEs, we found a strong correlation of H3K9me2/3 enrichment at regions with retained DNA methylation during mPGCLC specification and, conversely, an enrichment of H3K4me3 and H3K27ac at regions with faster than average demethylation. This suggests that the underlying chromatin signature influences both the global and the local demethylation rate in mouse germline development.

Loss of DNA methylation has generally been linked to activation of retrotransposons ([@bib3], [@bib59]), and in vivo piRNAs have been found to control TE expression ([@bib25]). Indeed, TE expression was low in substantially hypomethylated day-6 mPGCLCs and we found expression of piRNAs in in vitro mPGCLCs, suggesting that TE expression is also restrained by smRNA-dependent mechanisms in vitro. Since loss of piRNA activity causes male sterility ([@bib6], [@bib7], [@bib29]), mPGCLCs would seem to represent a good experimental system for the investigation of piRNA biology in the future. In hPGCLCs we found some extent of hERVK reactivation followed by progressive repression in hPGCs, also suggesting the activity of a DNA methylation-independent repressive mechanism in the human germline. Notably, we also observed a specific increase in the expression of SVA elements in naive hESC but not in similarly hypomethylated week-5.5 hPGCs, suggesting that the expression of SVA might be a specific marker of naive hESCs ([@bib54]).

We found a loss of primary methylation imprints in naive hESCs (confirming a recent study \[[@bib40]\]), which were not re-established during priming to hEpiLCs. Abnormal imprinting is linked to a range of human developmental disorders and malignancies ([@bib5]). While it is hoped that future developments of naive hESC derivation and culture protocols will resolve this issue, especially for the application of hESCs, whether there are any adverse implications of loss of imprinting for germline development is unclear at present. Finally, the current PGCLC system enables the characterization of early events of epigenetic reprogramming and its regulation in the mammalian germline, but further developments are required to also capture the later events of human PGC development. These will reveal the regulation and importance of piRNAs in the human germline and also shed light on the subsequent events of epigenetic reprogramming not assessed thus far.

Experimental Procedures {#sec4}
=======================

Human hESC Culture and hPGCLC Differentiation {#sec4.1}
---------------------------------------------

Naive H9 and naive WIBR3 *OCT4*-dPE-GFP hESCs were propagated in serum-free N2B27 medium (N2 & B27; Life Technologies) supplemented with 20 ng/mL hLIF (Cambridge Stem Cell Institute \[SCI\]), 1 μM MEK inhibitor PD0325901 (SCI), 3 μM GSK3 inhibitor CHIR99021 (SCI), and 2 μM protein kinase C inhibitor Gö6983 (Sigma-Aldrich), as described previously ([@bib18], [@bib51]). The medium was refreshed every day and cells were passaged every 4--5 days. hEpiLC were induced by plating 2 × 10^5^ naive hESCs on a well of a 6-well plate coated with growth factor reduced Matrigel (Corning) in N2B27 medium supplemented with 1 ng/mL TGF-β1 (Peprotech), 12 ng/mL bFGF (SCI), and 1% KSR (Gibco). The medium was changed every day. hPGCLCs were induced by plating 3--4 × 10^3^ day-4 hEpiLCs in a well of an Ultra-Low attachment U-bottom 96-well plate (Corning) in GK15 medium (Glasgow's minimal essential medium \[Life Technologies\] with 15% KSR \[Life Technologies\], 0.1 mM non-essential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, and 0.1 mM β-mercaptoethanol) supplemented with 500 ng/mL hBMP4 (R&D Systems), 20 ng/mL hLIF (SCI), 100 ng/mL hSCF (R&D Systems), and 50 ng/mL hEGF (R&D Systems). Cells were cultured in 5% O~2~ and 5% CO~2~ in a humidified incubator at 37°C.

Mouse mESC Culture and mPGCLC Differentiation {#sec4.2}
---------------------------------------------

Naive E14 or BVSC mESCs were cultured feeder-free in N2B27 supplemented with 10 ng/mL mLIF (SCI), 1 μM MEK inhibitor PD0325901 (SCI), and 3 μM GSK3 inhibitor CHIR99021 (SCI), together known as 2i ([@bib63]). The medium was refreshed every day and cells were passaged every 2--3 days. mEpiLC were induced by plating 1 × 10^5^ naive mESCs on a well of a 12-well plate coated with human plasma fibronectin (Millipore, FC010) in N2B27 medium supplemented with 20 ng/mL activin A (SCI), 12 ng/mL bFGF (SCI), and 1% KSR (Gibco) ([@bib21]). The medium was changed every day. mPGCLCs were induced by plating 2 × 10^3^ day-2 mEpiLCs in a well of an Ultra-Low attachment U-bottom 96-well plate (Corning) in GK15 medium supplemented with 500 ng/mL BMP4 (R&D Systems), 10 ng/mL mLIF (SCI), 100 ng/mL mSCF (R&D Systems), and 50 ng/mL mEGF (R&D Systems). mPGCLC were cultured in 5% O~2~ and 5% CO~2~ in a humidified incubator at 37°C.

In Vivo Prospermatogonia Collection {#sec4.3}
-----------------------------------

Embryonic samples were collected from timed mattings of C57Bl/6J female mice expressing an Oct-4/GFP transgene in the developing gonad ([@bib64]). Prospermatogonia were isolated as described previously ([@bib47]). All animal work carried out as part of this study is covered by a project license (to W.R.) under the 1986 Animal (Scientific Procedures) Act, and is further regulated by the Babraham Institute Animal Welfare, Experimentation, and Ethics Committee.

RNA-Seq, Mapping, and Analysis {#sec4.4}
------------------------------

Extracted total RNA was DNase treated and poly(A) enriched. RNA-seq libraries were prepared using the TruSeq RNA Library Prep Kit v2 (Illumina) or a modified SMART-Seq2 protocol ([@bib41]). Sequencing was performed on Illumina HiSeq 2000 instruments and RNA-seq sequences were trimmed using Trim Galore (v0.4.1, <http://www.bioinformatics.babraham.ac.uk/projects/trim_galore>/) using default settings. Trimmed data were separately mapped to the human GRCh37 or mouse GRCm38 genome assemblies using hisat2 (v2.0.5) with options \--sp 1000,1000 \--no-mixed \--no-discordant, and filtered to remove non-primary alignments or alignments with MAPQ \<20. Mapped RNA-seq data were quantitated using the RNA-seq quantitation pipeline in SeqMonk software ([www.bioinformatics.babraham.ac.uk/projects/seqmonk/](http://www.bioinformatics.babraham.ac.uk/projects/seqmonk/){#intref0015}).

small RNA-Seq, Mapping, and Analysis {#sec4.5}
------------------------------------

smRNA-seq libraries were generated using the Illumina TruSeq Small RNA Library Preparation Kit (RS-200-0012) with the following modifications. A total of 100 ng to 1 μg RNA input material was used. cDNA samples were run on 10% Novex PAGE gels for purification and the gel piece between the 145- and 160-bp marker excised, and cDNA was eluted from the gel in freshly prepared 0.3 M NaCl by rotation overnight at 4°C. The cDNA was precipitated in EtOH overnight; from the supernatant the cDNA was resuspended in 10 μL of EB buffer and the library was quantified using the high-sensitivity DNA chips on the Agilent Bioanalyzer. High-throughput sequencing of all libraries was carried out with single-end protocols on a HiSeq 2000 instrument (Illumina).

smRNA-seq data processing was performed using the freely available piRNA pipeline piPipes (<https://github.com/bowhan/piPipes>) ([@bib20]). smRNA-seq libraries were trimmed to remove poor-quality reads, adapters, and barcode sequences. Trimmed data were mapped using Bowtie against the mm9 genome build and specific relevant annotations: Gene-derived piRNA annotations were defined earlier ([@bib32]) and based on experimental data from mouse spermatogenesis. Repeats were defined in the analysis by using the mouse repeatmasker annotation (<http://www.repeatmasker.org>).

The plots shown were generated as described below. The distribution of smRNAs was computed by mapping all smRNA-seq reads to the individual genomic features. Unannotated reads were not shown in the graph. The length distribution was calculated taking all uniquely mapped smRNAs into account, excluding smRNAs mapping to rRNAs.

For all subsequent analysis, smRNA reads were pre-filtered as follows: reads mapping to rRNAs and miRNAs were excluded, then reads aligning to the repeat masked mm9 genome (all annotated repeats were masked/replaced by Ns) were also removed. The remaining smRNA reads were mapped to the mouse repeatmasker annotation. The 5′-end nucleotide composition was computed from the uniquely mapped smRNA. Similarly, analysis of the position of 5′ to 5′ overlap was performed on the mapped smRNA reads, and the length distribution and strand orientation of smRNAs shown was generated using uniquely mapped smRNA reads.

Bisulfite Sequencing, Mapping, and Analysis {#sec4.6}
-------------------------------------------

Whole-genome bisulfite libraries were generated from isolated DNA following published protocols ([@bib47]) or post-bisulfite adaptor tagging (PBAT) libraries were prepared directly from cell lysates following recently described protocols ([@bib34], [@bib48]). High-throughput sequencing of all libraries was carried out with a 125-bp paired-end protocol on a HiSeq 2000 instrument (Illumina).

Raw sequence reads from PBAT libraries were trimmed to remove poor-quality reads and adapter contamination using Trim Galore (v0.4.1). The remaining sequences were mapped using Bismark (v0.14.4) ([@bib28]) with the following set of parameters to the mouse reference genome GRCm38 or the human reference genome GRCh37 in paired-end mode: \--pbat to be able to count overlapping parts of the reads only once while writing out unmapped singleton reads; in a second step remaining singleton reads were aligned in single-end mode for read 1: \--pbat; or single-end mode for read 2: defaults. Reads were then deduplicated and CpG methylation calls were extracted from the deduplicated mapping output ignoring the first 6 bp of each read to reduce the methylation bias typically observed in PBAT libraries using the Bismark methylation extractor (v0.14.4) with the following parameters: (a) paired-end mode: \--ignore 6 \--ignore_r2 6; (b) single-end mode: \--ignore 6.

Raw sequence reads from WBGS libraries were trimmed to remove poor-quality reads and adapter contamination using Trim Galore (v0.4.1). The remaining sequences were mapped using Bismark (v0.14.4) ([@bib28]) with default parameters to the mouse reference genome GRCm38 or the human reference genome GRCh37 in paired-end mode. Reads were then deduplicated and CpG methylation calls were extracted from the deduplicated mapping output using the Bismark methylation extractor (v0.14.4) in paired-end mode.

CpG methylation calls were analyzed using R and SeqMonk software. Global CpG methylation levels of pooled replicates were illustrated using bean plots. The genome was divided into consecutive 20-kb probes covered by at least 10 CpGs, and percentage methylation was calculated using the bisulfite feature methylation pipeline in SeqMonk.

Probe trend plots were generated by calculating average CpG methylation levels of 1-kbp 500-bp overlapping probes from 5 kbp upstream of the transcriptional start site through gene bodies (which were scaled for visualization) to 5 kbp downstream of the transcriptional end site.

For analysis of specific genome features, these were defined as follows using the Ensembl gene set annotations for mouse and human: exons (probes overlapping exons), introns (probes overlapping introns), promoters (probes overlapping 1,000 bp upstream of genes), CGI promoters (promoters containing or within 250 bp of a CGI), non-CGI promoters (all other promoters), intergenic (probes not overlapping with gene bodies). Annotations for mouse and human germline imprint control regions were obtained from [@bib55] and [@bib10]. Pseudocolor heatmaps representing average methylation levels were generated using the R "heatmap.2" function without further clustering, scaling, or normalization.

For k-means clustering, average CpG methylation across 2-kb probes of the human genome were calculated using the bisulfite feature methylation pipeline in SeqMonk, excluding probes overlapping with repetitive elements. Seven clusters were generated, and enrichment of specific genomic features was assessed by counting the percentage overlap of probes in each cluster with the specific genomic features and comparing these with the whole genome.

Scatter plots visualizing the changes in global methylation were generated by plotting the percentage methylation over probes defined to contain 50 CpGs each. Scatter plots were colored according to the probe density or the density of the indicated overlapping genomic feature. Published raw ChIP-seq data were trimmed to remove poor-quality reads, adapters, and barcode sequences using Trim Galore (v0.4.1). Trimmed data were mapped using Bowtie2 against the mouse reference genome GRCm38 and filtered to remove non-primary alignments or alignments with MAPQ \<20. Read-count enrichments were overlaid on the methylation scatter plots. Pseudocolor scatter plots were generated using R.

Correlation between gene body methylation and gene expression was computed from average CpG methylation across gene bodies using the bisulfite feature methylation pipeline in SeqMonk and correlating these values with the respective gene expression values for each gene.

Repeat Analysis {#sec4.7}
---------------

Repeat locations for a pre-defined set of repeat classes of interest were extracted from the pre-masked repeatmasker libraries (mouse, repeatmasker v4.0.3, library version 20130422; human, repeatmasker v4.0.5, library version 20140131). Repeat instances within 2 kb of an annotated gene in the Ensembl gene set were removed to avoid mixing signals from genic expression with specific expression of repetitive sequences.

RNA-seq sequences were processed and mapped as described above (RNA-Seq, Mapping, and Analysis). Non-directional overlaps were quantitated between the mapped RNA-seq reads and the repeat instances. Summed counts for all instances of each class of repeat were calculated, and these were corrected for both the total length of all repeats and the size of the individual libraries to generate RPKM (reads per kilobase of transcript per million mapped reads) expression values. The matrix of expression values and samples was plotted using the R pheatmap library.

Bisulfite sequencing libraries were processed and mapped as described above (Bisulfite Sequencing, Mapping, and Analysis). Methylation levels at the repeat instances were quantitated by summing up all methylation calls and non-methylation calls for all instances of each class of repeat and calculating the percentage of methylated calls over all calls. The matrix of expression values and samples was plotted using the R pheatmap library.

See also [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Author Contributions {#sec5}
====================
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Accession Numbers {#app1}
=================

The accession number for the next-generation sequencing data reported in this study is GEO: [GSE86586](ncbi-geo:GSE86586){#intref0030}.

Note Added in Proof {#app4}
===================

During the revision of this manuscript another study reported global loss of DNA methylation and imprint erasure in in vitro mPGCLCs (Miyoshi et al. 2016), supporting the usefulness of the PGCLC system and confirming our observations. REF: Miyoshi, N., Stel, J. M., Shioda, K., Qu, N., Odahima, J., Mitsunaga, S., et al. (2016). Erasure of DNA methylation, genomic imprints, and epimutations in a primordial germ-cell model derived from mouse pluripotent stem cells. *Proceedings of the National Academy of Sciences of the United States of America.* [http://doi.org/10.1073/pnas.1610259113](10.1073/pnas.1610259113){#interref0010}.
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![Specification of hPGCLCs from Naive Human Embryonic Stem Cells\
(A) Schematic protocol for specification of hPGCLCs from naive hESCs. In brief, naive hESCs were primed to hEpiLCs for 4 days in the presence of bFGF, TGF-β, and KSR. Subsequently, day-4 hEpiLCs were aggregated to EBs and cultured in medium containing hBMP4, hSCF, hEGF, and hLIF.\
(B) Bright-field images of naive hESCs, primed day-4 hEpiLCs, and day-12 hEBs, and fluorescence images of *OCT4*-dPE promoter-driven GFP expression in hEBs. Scale bars, 200 μm.\
(C) FACS analysis of dissociated day 0--12 hEBs with anti-cKIT-Alexa Fluor 647 to detect hPGCLCs. Box shows the percentage of cKIT-positive cells at each time point.\
(D) Immunofluorescence of day-12 hEB sections showing expression of OCT4 (green) or SOX17 (green) and DNA staining with DAPI (blue). Scale bars, 10 μm.\
(E) Immunofluorescence of fixed cKIT^+^ sorted day-12 hPGCLCs showing expression of BLIMP1 (green) and DNA staining with DAPI (blue). Scale bars, 10 μm.\
(F) mRNA expression analysis of conventional and naive hESCs, primed day-4 hEpiLCs, sorted hPGCLCs, and published in vivo datasets of hPGCs and somatic cells ([@bib52]). Error bars indicate mean ± SD from three biological samples.\
(G) PCA of RNA-seq data from human naive hESC, primed day-4 (d4) hEpiLCs, and hPGCLCs. PC1 and PC2 were calculated using the R library "FactoMineR," excluding very lowly expressed genes.\
(H) PCA of RNA-seq data from mouse naive mESC, primed day-2 mEpiLCs, and mPGCLCs. PC1 and PC2 were calculated using the R library "FactoMineR," excluding very lowly expressed genes.\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![DNA Methylation Dynamics during Human and Mouse PGCLC Specification\
(A) Bean plots showing the distribution of CpG methylation levels of pooled replicates of human sperm, oocytes, ICM, naive hESCs, primed EpiLCs, PGCLCs, and in vivo PGCs. Methylation was quantitated over 20-kb genomic probes covered by at least ten CpGs.\
(B) Bean plots showing distribution of CpG methylation levels of pooled replicates of mouse sperm, oocytes, ICM, naive ESCs, epiblast, primed EpiLCs, PGCLCs, and in vivo PGCs. Methylation was quantitated over 20-kb genomic probes covered by at least ten CpGs.\
(C) mRNA expression levels of key enzymes involved in DNA methylation dynamics in human naive hESCs, primed hEpiLCs, hPGCLCs, and in vivo PGCs. Heatmap shows the average expression (log~2~) of three biological replicates.\
(D) Averaged CpG methylation profiles over all human annotated genes starting from 5 kb upstream (−5 kb) of the transcription start site (TSS), through scaled gene bodies to 5 kb downstream (+5 kb) of transcription end site (TES).\
(E) Averaged CpG methylation of indicated genomic features in the human methylation datasets.\
(F) Averaged CpG methylation of known DMRs of imprinted maternal and paternal genes in the human methylation datasets.\
(G) k-Means clustering of 2-kb probes of the human genome, excluding probes overlapping with repetitive elements. Seven clusters were generated and the enrichment of specific genomic features compared with the whole genomes was assessed.\
Published datasets from human sperm, oocytes ([@bib39]), ICM ([@bib16]), naive ESCs ([@bib51]), in vivo PGCs ([@bib52]), and mouse sperm, oocytes, ICM ([@bib60]), naive ESCs ([@bib12]), epiblast, and in vivo PGCs ([@bib47]) were included in the analysis. Biological replicates were pooled and average levels were used for the analysis. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Regulation of Local Methylation Dynamics during Human and Mouse PGCLC Specification\
(A) Scatter plots of CpG methylation percentages over probes spanning 50 CpGs comparing primed day-4 hEpiLCs and day-12 hPGCLCs. The scatter plots were overlaid with red or blue to highlight probes with higher or lower levels of CpG methylation than the background model (p \< 0.05) or labeled to highlight CpG density, overlap with gene bodies, SVA, or L1Pa elements.\
(B) Representative bisulfite-sequencing data showing a part of chromosome 2 from hICM, hESC, primed hEpiLC, hPGCLC, and in vivo hPGC datasets. Regions retaining higher levels of DNA methylation and overlapping with SVA elements or gene bodies are shaded in green or red, respectively. The position of genes, CGIs, and SVA or L1PA elements is shown in the top panel.\
(C) Box plots of the CpG methylation levels of probes defined in (A) as methylated higher or lower than the background model. Shown are samples across the whole hPGC/hPGCLC specification period. The middle line indicates the median of the data, the upper and lower extremities of the box show the 25^th^ and 75^th^ percentiles, and the upper and lower black whiskers show the median ± the interquartile range (25%--75%) multiplied by 2. Any individual points that fall outside this range are shown as filled circles. Each circle represents a single probe.\
(D) Scatter plots of CpG methylation percentages over probes spanning 50 CpGs comparing primed day-2 mEpiLCs and day-6 mPGCLCs. The scatter plots were overlaid with red or blue to highlight probes with higher or lower levels of CpG methylation than the background model (p \< 0.05) or labeled by their CpG density or the density of overlapping IAPs. Published histone ChIP-seq datasets for H3K9me2, H3K9me3, H3K27ac, and H3K4me3 were used to label probes enriched in the respective marks, according to their ChIP-seq read-count enrichment.\
(E) Expression of histone 3 lysine 9 methyltransferases (KMTs) and demethylases (KDMs) in mouse naive mESC, primed day-2 mEpiLC, mPGCLC, and in vivo mPGC datasets. *Suv39h1*/*2* and *Kdm4a*/*b*/*c* are H3K9me3 specific, while *Ehmt1*/*2* and *Kdm3a*/*b* are specific for H3K9me1/2. The heatmap shows the average expression (log~2~) of three biological replicates.\
Published datasets from human ICM ([@bib16]), naive ESCs ([@bib51]), in vivo PGCs ([@bib52]), mouse in vivo PGCs ([@bib47]) and ChIP-seq ([@bib30], [@bib33]) were included in the analysis. Biological replicates were pooled and average levels were used for the analysis. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Methylation Dynamics and Transcriptional Regulation of Transposable Elements\
(A) Averaged CpG methylation of major human repetitive elements in human datasets.\
(B) Averaged CpG methylation of major murine repetitive elements in mouse datasets.\
(C) Averaged expression of major murine repetitive elements in mouse poly(A)-enriched RNA-seq datasets. Repeat locations were extracted from the pre-masked repeatmasker libraries and repeat instances within 2 kb of an annotated gene were removed.\
(D) Expression of key enzymes involved in smRNA biogenesis and function in mouse naive mESCs, primed day-2 mEpiLCs, mPGCLCs, and in vivo mPGCs. The heatmap shows the average expression (log~2~) of biological replicates.\
(E) Distribution of reads from smRNA-seq libraries from day-6 mPGLCLs, in vivo prospermatogonia, and mESCs over different classes of smRNAs as defined previously ([@bib20], [@bib32]). smRNAs mapping to (gene-derived) piRNAs are highlighted.\
(F) Length distribution of all uniquely mapped smRNAs, excluding rRNAs, in day-6 mPGCLCs. The average length of miRNAs (22 nt) and piRNAs (24--31 nt) is highlighted.\
(G) Nucleotide composition of the 5′ ends ± 30 nt of all smRNAs from day-6 mPGCLCs uniquely mapped to repetitive elements (defined by repeatmasker).\
(H) Ping-pong (5′ to 5′ overlap) analysis of normalized reads from day-6 mPGCLCs mapped to repetitive elements (defined by repeatmasker).\
(I) Length distribution of smRNAs from day-6 mPGCLCs assigned to sense (blue) and antisense (red) strands of reads uniquely mapped to repetitive elements (defined by repeatmasker).\
Published datasets from human sperm, oocytes ([@bib39]), ICM ([@bib16]), naive ESCs ([@bib51]), in vivo PGCs ([@bib52]), and mouse sperm, oocytes, ICM ([@bib60]), naive ESCs ([@bib12]), epiblast, and in vivo PGCs ([@bib47]) were included in the analysis. Biological replicates were pooled and average levels were used for the analysis. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}
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